Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents
NCT02219373Phase 3Withdrawn
- Sponsor
- Boston Children's Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic neuropathic pain comparing Gabapentin, Oxcarbazepine and Placebo (3 arms). Primary endpoint: Reductions in pain scores at 8 weeks. Planned start Jun 2026; status: withdrawn.
02
Drugs
gabapentinoxcarbazepine
03
Conditions
chronic neuropathic pain
Beyond the preview
Go deeper on NCT02219373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219373.